Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors

BACKGROUND: Selected patients with advanced non-small cell lung cancer (NSCLC) benefit from immunotherapy, especially immune checkpoint inhibitors such as PD-1 (programmed cell death protein 1) inhibitor. Peripheral blood biomarkers would be most convenient to predict treatment outcome and immune-re...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Lihong, Wang, Yong, Liu, Fen, Qiu, Xiaotong, Zhang, Xinwei, Fang, Chen, Qian, Xiaoyin, Li, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413896/
https://www.ncbi.nlm.nih.gov/pubmed/32350592
http://dx.doi.org/10.1007/s00262-020-02585-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7413896/
https://www.ncbi.nlm.nih.gov/pubmed/32350592
http://dx.doi.org/10.1007/s00262-020-02585-w

Ejemplares similares